Pneumococcal immunization and public health: the Canadian experience.
Pneumococcal vaccine has been poorly used in Canada, despite strong recommendations for its use by the Canadian National Advisory Committee on Immunization. In a recent survey of health officials, however, seven of the 12 Canadian provinces and territories were found to either have a programme for all persons > 65 years of age or were planning to implement one within the next year. Factors that have contributed to this increased interest include: better data on disease incidence and preventable illness from population-based surveillance; data on emerging resistance of Streptococcus pneumoniae in Canada to penicillin and other antimicrobials; implementation of vaccine programmes for the elderly by public health officials in Ontario, Nova Scotia and British Columbia; completion of a cost-benefit study of pneumococcal vaccine for Canada; and increased attention to pneumococcal vaccination at national immunization meetings and in the medical literature. Increased availability of vaccine and competitive pricing are also making programmes for the elderly more feasible and affordable. A national meeting entitled 'Preventing Pneumococcal Disease: A Canadian Consensus Conference' was held in February 1998 to further build on this growing interest.
Spika
J S
JS
Bureau of Infectious Diseases, Laboratory Centre for Disease Control, Health Canada, Ottawa, Ontario.
Keresz
D
D
Deeks
S
S
Talbot
J A
JA
D002170:Canada / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs / Q000639:trends*; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D011634:Public Health / Q000639:trends*; D013296:Streptococcus pneumoniae / Q000276:immunology*